Olympus transfers Evident to Bain Capital management fund to accelerate growth and innovation.

Tokyo, August 29, 2022

Olympus Corporation (“Olympus”) and EVIDENT Co., Ltd. (“Evident”), a wholly owned subsidiary of Olympus, announces that Olympus has entered into an agreement with Bain Capital Private Equity, LP (“Bain Capital”) regarding the transfer of Evident. Based on this agreement, all shares of Evident will be transferred to Bain Capital on January 4, 2023, if the terms and conditions of the transfer are approved.

In order to achieve sustainable growth as a global medical technology company, Olympus is working to strengthen management by allocating resources to the Medical business, focusing on the Internal Solutions segment. Scan and Therapeutic Solutions. Olympus's Science Solutions business was transformed into a subsidiary of Evident in April 2022; This decision was made to promote growth, improve profitability and contribute to the enhancement of the corporate value of Olympus as a whole by establishing a management system tailored to the characteristics of each business in the entertainment industry. medical and scientific law.

Evident, a spin-off of Olympus's Science Solutions division, operates in the life sciences and industrial applications sectors. Microscopes used for life sciences support the areas of clinical and academic research, pathological diagnostic services, and the recent growing need for drug discovery and fertility treatment. . Evident's industrial solutions range from Microscopes used in the semiconductor sector and the electronic components market is expanding to industrial endoscopes, non-destructive testing equipment and fluorescence analyzers. X-ray optics are used in industrial applications such as automobile manufacturing, aviation, metal production, energy, etc.

In a favorable market environment, Olympus concluded that it would be the most profitable solution to transfer all of Evident's shares to Bain Capital and allow Evident to grow its business with agile and flexible decision making. more responsive to market needs, grow better and develop more innovative solutions for its customers.

“Bain Capital deeply understands the business value and growth potential of Evident. More importantly, the fund appreciates Evident's corporate culture, which is a valuable asset of Olympus in meeting the diverse needs of customers through global cooperation and proactive commercialization. advanced technologies,” said Yasuo Takeuchi, President and CEO of Olympus Corporation. “They have the ability to provide Evident with a business environment that best suits their business characteristics, which can maximize business value in a sustainable way. I believe that Bain Capital is the best partner for Evident,” added Takeuchi.

Yoshitake Saito, President and Representative Director of Evident, commented on the focus of the new company: “Evident will continue to operate under the umbrella of Bain Capital to provide customers with innovative products and services. created globally. Building on our seasoned expertise, we will expand our engineering technologies, including cloud-based solutions, to enhance customer experience and improve overall workflow in one number of areas of research and examination. With greater management autonomy, we will foster agile and open innovation, which will accelerate product development to address customer challenges.”

About the company Evident:

• Company name: Evident Corporation
• Registered headquarters: Tatsuno-machi, Kamiina-gun, Nagano, Japan
• Headquarters: Shinjuku, Tokyo, Japan
• President and Representative Director: Yoshitake Saito
• Business: Develops, manufactures, sells and supplies solutions for biological microscopes, industrial microscopes, film cameras and industrial endoscopes, non-destructive testing equipment and machines X-ray analysis.
• Capital: 24,000 million JPY (as of June 30, 2022)
• Number of employees (global): Approximately 4,000

Olympus will continue to support Evident during the business transition. Going forward, Olympus will focus on the medical field, with efforts to make people's lives healthier, safer and more fulfilling. Driven by the spirit of science and focused on innovation, Evident will continue to provide and expand services and solutions for life science and industrial applications.

For details on a specific subsidiary's share transfer, please refer to Olympus' corporate disclosure at https://www.olympus-global.com/news/ir/2022/

About Bain Capital investment fund

Bain Capital is an American-owned private investment firm headquartered in Boston. The firm specializes in private equity, venture capital, credit, public equity, impact investing, life sciences and real estate. Bain Capital invests across a wide range of industries and geographies.

Since its inception, the fund has invested in or acquired hundreds of companies including AMC Theatre, Artisan Entertainment, Aspen Education Group, Apex Tool Group, Brookstone, Burger King, Burlington Coat Factory, Canada Goose, DIC Entertainment, Domino's Pizza, DoubleClick, Dunkin' Donuts , D&M Holdings, Guitar Center, Hospital Corporation of America (HCA), iHeartMedia, ITP Aero, KB Toys, Sealy, Sports Authority, Staples, Toys “R” Us, Virgin Australia, Warner Music Group , Fingerhut, The Weather Channel, Apple Leisure Group and more recently Evident Corp under Olympus.

• Assets under management: $155 billion (2020)
• Founding Date: 1984, Boston, Massachusetts, USA
• Headquarters: Boston, Massachusetts, USA
• Subsidiaries: Bain Capital Ventures, Bain Capital Credit
• Founders: Mitt Romney, Bill Bain